Torsten Haferlach

发表

Automated morphological analysis of bone marrow cells in microscopic images for diagnosis of leukemia: nucleus-plasma separation and cell classification using a hierarchical tree model of hematopoesis

Christian Münzenmayer, Sebastian Krappe, Thomas Wittenberg, 2016, SPIE Medical Imaging.

Lokalisierung von Knochenmarkzellen für die automatisierte morphologische Analyse von Knochenmarkpräparaten

Christian Münzenmayer, Sebastian Krappe, Thomas Wittenberg, 2014, Bildverarbeitung für die Medizin.

Dynamic Programming for the Segmentation of Bone Marrow Cells

Can Fahrettin Koyuncu, A. Enis Çetin, Christian Münzenmayer, 2015, Bildverarbeitung für die Medizin.

Automated classification of bone marrow cells in microscopic images for diagnosis of leukemia: a comparison of two classification schemes with respect to the segmentation quality

Christian Münzenmayer, Sebastian Krappe, Thomas Wittenberg, 2015, Medical Imaging.

Integration of clinical and genetic information - from patient data to gene expression analysis

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2002, Silico Biol..

Quantitative comparison of microarray experiments with published leukemia related gene expression signatures

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2009, BMC Bioinformatics.

Bioinformatics for Medical Diagnostics: Assessment of Microarray Data in the Context of Clinical Databases

Martin Dugas, Torsten Haferlach, Stefan Kääb, 2003, AMIA.

Automatic Detection of Relevant Regions for the Morphological Analysis of Bone Marrow Slides

Christian Münzenmayer, Sebastian Krappe, Thomas Wittenberg, 2016, Bildverarbeitung für die Medizin.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA

Kahn Rhrissorrakrai, Torsten Haferlach, Wolfgang Kern, 2019, PLoS Comput. Biol..

Human and artificial intelligence to illuminate MDS.

Torsten Haferlach, 2020, Blood.

WGS and WTS in leukaemia: A tool for diagnostics?

Torsten Haferlach, Manja Meggendorfer, Wencke Walter, 2020, Best practice & research. Clinical haematology.

The power and potential of integrated diagnostics in acute myeloid leukaemia

Torsten Haferlach, Ines Schmidts, T. Haferlach, 2019, British journal of haematology.

Impact of integrating clinical and genetic information

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2001, German Conference on Bioinformatics.

An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma

Torsten Haferlach, Wolfgang Kern, Peter M. Krawitz, 2018, Blood.

Méthode pour distinguer les différents prognostics de la LMA

Torsten Haferlach, Wolfgang Kern, Claudia Schoch, 2003 .

Next-generation diagnostics for precision oncology: preanalytical considerations, technical challenges, and available technologies.

Torsten Haferlach, Nicole Pfarr, Wilko Weichert, 2020, Seminars in cancer biology.

Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes

Torsten Haferlach, Peter M. Krawitz, Max Zhao, 2019 .

R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data

Martin Dugas, Hans-Ulrich Klein, Christoph Bartenhagen, 2011, Bioinform..

Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms

Torsten Haferlach, Wolfgang Kern, Peter M. Krawitz, 2021, Patterns.

Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set

Christian Münzenmayer, Carsten Marr, Sebastian Krappe, 2021, Blood.

Integration of next-generation sequencing into clinical practice: are we there yet?

Torsten Haferlach, Alexander Kohlmann, Vera Grossmann, 2012, Seminars in oncology.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Should clinical hematologists put their microscopes on eBay?

Torsten Haferlach, T. Haferlach, Mars van’t Veer, 2014, Haematologica.

The Use of Unique Molecular Identifiers (UMIs) Strongly Improves Sequencing Detection Limits Allowing Earlier Detection of Small TP53 Mutated Clones in Leukemias

Torsten Haferlach, Wolfgang Kern, Claudia Haferlach, 2016 .

Color Atlas of Hematology: Practical Microscopic and Clinical Diagnosis

Torsten Haferlach, T. Haferlach, 2004 .

Expression of IGFBP7 in acute leukemia is regulated by DNA methylation

Torsten Haferlach, Andrea Stroux, Wolf-Karsten Hofmann, 2011, Cancer science.

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

Torsten Haferlach, Giuseppe Basso, Robin Foà, 2008, British journal of haematology.

Modern diagnostics in acute leukemias.

Torsten Haferlach, Wolfgang Kern, Claudia Schoch, 2005, Critical reviews in oncology/hematology.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Roberta Spinelli, Rocco Piazza, Torsten Haferlach, 2012, Nature Genetics.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Paola Fazi, Marco Vignetti, Hans-Ulrich Klein, 2010, Blood.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases

Martin Dugas, Torsten Haferlach, Lars Bullinger, 2008 .

First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2012 .

Which compartments are involved in Philadelphia‐chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques

Torsten Haferlach, Claudia Schoch, Robert Schoch, 1997, British journal of haematology.

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, British journal of haematology.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2002 .

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Torsten Haferlach, Guido Marcucci, Hartmut Döhner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

The role of multiparameter flow cytometry for disease monitoring in AML.

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2010, Best practice & research. Clinical haematology.

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms

Masao Nagasaki, Satoru Miyano, Yuichi Shiraishi, 2012, Nature Genetics.

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

Torsten Haferlach, Philipp Erben, Thomas Ernst, 2012, Annals of Hematology.

AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia

Torsten Haferlach, Daniel G. Tenen, Claudia Schoch, 2001, Nature Medicine.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

Torsten Haferlach, Stefano Volinia, Carlo M. Croce, 2008, Proceedings of the National Academy of Sciences.

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, 2005, Genes, chromosomes & cancer.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, Genes, chromosomes & cancer.

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Torsten Haferlach, Peter Vandenberghe, Jason Gotlib, 2012, Expert review of hematology.

Color Atlas of Hematology

Torsten Haferlach, T. Haferlach, H. Diem, 2004 .

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.

Torsten Haferlach, Alexander Kohlmann, Wolf-Karsten Hofmann, 2009, Blood.